Table 7.
Neonatal calf clinical model for efficacy of bumped kinase inhibitor 1369 against Cryptosporidium parvum.
| Experimental groups | Total urine output (L) |
Net weight gain (% change) |
BKI 1369 plasma conc. at 12 h after 2nd dose (Avg ± S.D.) (μM) |
Metabolite 1 plasma conc. at 12 h after 2nd dose (Avg ± S.D.) (μM) |
Metabolite 2 plasma conc. at 12 h after 2nd dose (Avg ± S.D.) (μM) |
Highest observed BKI 1369 conc. in faeces (Avg ± S.D.) (μM) |
|---|---|---|---|---|---|---|
| Control (n = 3) | 30.2 | −0.06 | NA | NA | NA | NA |
| Treated (n = 4) | 53.7 | +4.7 | 5.3 ± 2.4 | 0.2 ± 0.1 | 8.8 ± 3.5 | 9.4 ± 6.1 |
Calves were treated twice daily with oral doses (5 mg/kg of body weight) of bumped kinase inhibitor 1369 for 5 days.
Conc., concentration; NA, not applicable; Avg, average.